- Home
- PLRX vs EYPT Comparison
PLRX vs EYPT Comparison
Compare PLRX & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- EYPT
- Stock Information
- Founded
- PLRX 2015
- EYPT 1987
- Country
- PLRX United States
- EYPT United States
- Employees
- PLRX N/A
- EYPT N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- PLRX Health Care
- EYPT Industrials
- Exchange
- PLRX Nasdaq
- EYPT Nasdaq
- Market Cap
- PLRX 89.0M
- EYPT 741.0M
- IPO Year
- PLRX 2020
- EYPT 2005
- Fundamental
- Price
- PLRX $1.53
- EYPT $13.60
- Analyst Decision
- PLRX Hold
- EYPT Strong Buy
- Analyst Count
- PLRX 10
- EYPT 6
- Target Price
- PLRX $3.93
- EYPT $25.83
- AVG Volume (30 Days)
- PLRX 723.9K
- EYPT 767.8K
- Earning Date
- PLRX 11-06-2025
- EYPT 11-06-2025
- Dividend Yield
- PLRX N/A
- EYPT N/A
- EPS Growth
- PLRX N/A
- EYPT N/A
- EPS
- PLRX N/A
- EYPT N/A
- Revenue
- PLRX N/A
- EYPT $51,898,000.00
- Revenue This Year
- PLRX N/A
- EYPT N/A
- Revenue Next Year
- PLRX N/A
- EYPT N/A
- P/E Ratio
- PLRX N/A
- EYPT N/A
- Revenue Growth
- PLRX N/A
- EYPT 2.99
- 52 Week Low
- PLRX $1.10
- EYPT $3.91
- 52 Week High
- PLRX $16.10
- EYPT $14.42
- Technical
- Relative Strength Index (RSI)
- PLRX 44.68
- EYPT 65.67
- Support Level
- PLRX $1.66
- EYPT $12.88
- Resistance Level
- PLRX $1.85
- EYPT $14.42
- Average True Range (ATR)
- PLRX 0.13
- EYPT 0.78
- MACD
- PLRX -0.02
- EYPT 0.05
- Stochastic Oscillator
- PLRX 5.26
- EYPT 74.05
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.